These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 26444633)

  • 1. CD47 blockade as another immune checkpoint therapy for cancer.
    Vonderheide RH
    Nat Med; 2015 Oct; 21(10):1122-3. PubMed ID: 26444633
    [No Abstract]   [Full Text] [Related]  

  • 2. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
    Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
    Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors.
    Liu X; Pu Y; Cron K; Deng L; Kline J; Frazier WA; Xu H; Peng H; Fu YX; Xu MM
    Nat Med; 2015 Oct; 21(10):1209-15. PubMed ID: 26322579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy.
    Veillette A; Chen J
    Trends Immunol; 2018 Mar; 39(3):173-184. PubMed ID: 29336991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer immunotherapy targeting the CD47/SIRPα axis.
    Weiskopf K
    Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies.
    Dheilly E; Moine V; Broyer L; Salgado-Pires S; Johnson Z; Papaioannou A; Cons L; Calloud S; Majocchi S; Nelson R; Rousseau F; Ferlin W; Kosco-Vilbois M; Fischer N; Masternak K
    Mol Ther; 2017 Feb; 25(2):523-533. PubMed ID: 28153099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD47 checkpoint data supercharge Stanford spinout IPO.
    Dolgin E
    Nat Biotechnol; 2018 Aug; 36(8):671-672. PubMed ID: 30080839
    [No Abstract]   [Full Text] [Related]  

  • 8. The overall potential of CD47 in cancer immunotherapy: with a focus on gastrointestinal tumors.
    Tzatzarakis E; Hissa B; Reissfelder C; Schölch S
    Expert Rev Anticancer Ther; 2019 Nov; 19(11):993-999. PubMed ID: 31686549
    [No Abstract]   [Full Text] [Related]  

  • 9. CD47: the next checkpoint target for cancer immunotherapy.
    Feng R; Zhao H; Xu J; Shen C
    Crit Rev Oncol Hematol; 2020 Aug; 152():103014. PubMed ID: 32535479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perspectives on anti-CD47 antibody treatment for experimental cancer.
    Unanue ER
    Proc Natl Acad Sci U S A; 2013 Jul; 110(27):10886-7. PubMed ID: 23784781
    [No Abstract]   [Full Text] [Related]  

  • 11. Durable antitumor responses to CD47 blockade require adaptive immune stimulation.
    Sockolosky JT; Dougan M; Ingram JR; Ho CC; Kauke MJ; Almo SC; Ploegh HL; Garcia KC
    Proc Natl Acad Sci U S A; 2016 May; 113(19):E2646-54. PubMed ID: 27091975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective CD47 targeting with a bispecific antibody.
    Ferlin W; Masternak K; Shang L
    Cancer Immunol Immunother; 2021 Apr; 70(4):1161-1162. PubMed ID: 33388996
    [No Abstract]   [Full Text] [Related]  

  • 13. A novel fully human anti-CD47 antibody as a potential therapy for human neoplasms with good safety.
    Yu XY; Qiu WY; Long F; Yang XP; Zhang C; Xu L; Chang HY; Du P; Hou XJ; Yu YZ; Zeng DD; Wang S; Sun ZW
    Biochimie; 2018 Aug; 151():54-66. PubMed ID: 29864508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Macrophage 'Do not eat me' signal, CD47, is a clinically validated cancer immunotherapy target.
    Takimoto CH; Chao MP; Gibbs C; McCamish MA; Liu J; Chen JY; Majeti R; Weissman IL
    Ann Oncol; 2019 Mar; 30(3):486-489. PubMed ID: 30689700
    [No Abstract]   [Full Text] [Related]  

  • 15. On the mechanism of CD47 targeting in cancer.
    Zhao XW; Matlung HL; Kuijpers TW; van den Berg TK
    Proc Natl Acad Sci U S A; 2012 Oct; 109(42):E2843; author reply E2844-5. PubMed ID: 22923695
    [No Abstract]   [Full Text] [Related]  

  • 16. The identification of a CD47-blocking "hotspot" and design of a CD47/PD-L1 dual-specific antibody with limited hemagglutination.
    Shi R; Chai Y; Duan X; Bi X; Huang Q; Wang Q; Tan S; Gao GF; Zhu J; Yan J
    Signal Transduct Target Ther; 2020 Mar; 5(1):16. PubMed ID: 32296041
    [No Abstract]   [Full Text] [Related]  

  • 17. [Cellular immunotherapy as combination partners for the immune checkpoint blockade].
    Rössig C
    Oncol Res Treat; 2014; 37 Suppl 4():14-5. PubMed ID: 25301192
    [No Abstract]   [Full Text] [Related]  

  • 18. Donor CD47 controls T cell alloresponses and is required for tolerance induction following hepatocyte allotransplantation.
    Zhang M; Wang H; Tan S; Navarro-Alvarez N; Zheng Y; Yang YG
    Sci Rep; 2016 May; 6():26839. PubMed ID: 27230788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cancer immunotherapy by immuno-checkpoint blockade].
    Kawakami Y
    Rinsho Ketsueki; 2015 Oct; 56(10):2186-94. PubMed ID: 26458459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD47 expression in Epstein-Barr virus-associated gastric carcinoma: coexistence with tumor immunity lowering the ratio of CD8
    Abe H; Saito R; Ichimura T; Iwasaki A; Yamazawa S; Shinozaki-Ushiku A; Morikawa T; Ushiku T; Yamashita H; Seto Y; Fukayama M
    Virchows Arch; 2018 Apr; 472(4):643-651. PubMed ID: 29536167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.